The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker predicted that 2024 will turn out largely better than expected, too, as new products build momentum.
The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker predicted that 2024 will turn out largely better than expected, too, as new products build momentum.